简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2024-04-08 19:20 New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease
2024-04-07 12:57 Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
2024-04-03 19:17 Worldwide Anti-Smoking Policies Charted in Comprehensive Index
2024-04-02 18:51 Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
2024-04-02 10:41 KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
2024-03-29 12:39 Philip Morris International Demonstrates Clear Progress Toward Its Purpose as It Releases 2023 Integrated Report
2024-03-29 12:34 Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
2024-03-27 18:53 Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
2024-03-27 08:54 Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
2024-03-25 17:24 Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
2024-03-25 14:02 AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for $770 Million USD
2024-03-21 09:22 Merck Invests More than € 300 Million in New Life Science Production Site in Korea
2024-03-20 16:13 Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
2024-03-19 14:13 AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
2024-03-19 12:49 Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row
2024-03-18 11:11 BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
2024-03-14 09:18 Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
2024-03-13 13:30 BIO KOREA 2024: Registration Open for Business Partnering
2024-03-13 11:56 Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
2024-03-12 15:56 Nine Hospitals from Aster DM Healthcare Recognized in Newsweek’s ‘World's Best Hospitals 2024’ List

Business Wire Weibo

Press Releases

Latest Releases